Staffan Strömberg

Staffan Strömberg is currently Chief Executive Officer at Infant Bacterial Therapeutics AB since 2013.
Current roles also include Director positions at Cycle Pharmaceuticals AB, Eteboxagu AB, and BioGaia Pharma AB, as well as Head-Medical Devices at The Medical Products Agency.
Former roles include Chief Executive Officer at Tenova Bioplastics AB from 2010 to 2012, Director at Genetic Analysis AS from 2020 to 2023, Vice President at Nicox SA from 2005 to 2009, Head-Research & Development at Swedish Orphan Biovitrum International AB from 1998 to 2002, and Head-Medical Devices at Läkemedelsverket from 2009 to 2010.
Education includes graduate and doctorate degrees from the Royal Institute of Technology.